Skip to main content
Shedir Pharma Group logo

Shedir Pharma Group — Investor Relations & Filings

Ticker · SHE ISIN · IT0005379620 LEI · 81560092B300849E9017 XMIL Manufacturing
Open in API
Filings indexed 124 across all filing types
Latest filing 2023-04-03 Transaction in Own Shar…
Country IT Italy
Listing XMIL SHE

About Shedir Pharma Group

https://www.shedirpharmagroup.com

Shedir Pharma Group specializes in the research, development, formulation, and commercialization of health and wellness products. The company's portfolio encompasses nutraceuticals, dermocosmetics, medical devices, and pharmaceuticals. A key focus is on innovation, resulting in the creation of unique and patented product formulations that cover approximately 15 therapeutic areas. The group operates through specialized subsidiaries that manage the entire product lifecycle, from initial research and intellectual property to marketing and distribution. Products are offered in various forms, such as capsules, tablets, powders, liquids, and gels, targeting professionals in the medical and pharmaceutical sectors.

Recent filings

Filing Released Lang Actions
AGGIORNAMENTO SULL’ESECUZIONE DEL PROGRAMMA DI ACQUISTO AZIONI PROPRIE
Transaction in Own Shares Classification · 99% confidence The document is an official communication (Informazione Regolamentata) from SHEDIR PHARMA GROUP concerning the 'AGGIORNAMENTO SULL'ESECUZIONE DEL PROGRAMMA DI ACQUISTO AZIONI PROPRIE' (Update on the Execution of the Own Share Purchase Program). This explicitly details transactions where the company bought back its own shares during a specific period (March 27 to March 31, 2023), including daily transaction tables. This activity directly corresponds to the definition of 'Transaction in Own Shares' (share repurchase/issuance). The code for this is POS.
2023-04-03 Italian
SHEDIR PHARMA GROUP: BILANCIO 2022 - RICAVI (+20%) ED EBITDA (+30%) RISPETTO AL 2021
Earnings Release Classification · 98% confidence The document is a press release from Shedir Pharma Group dated March 31, 2023, announcing key financial results for the year ended December 31, 2022 (Ricavi (+20%) ED EBITDA (+30%) RISPETTO AL 2021). It explicitly states that the Board of Directors approved the draft annual financial statements ('progetto di bilancio d'esercizio al 31 Dicembre 2022') and the consolidated financial statements ('bilancio consolidato al 31 Dicembre 2022'). It also details the proposed dividend and the date for the Shareholders' Meeting to approve the financial statements. Although it contains summarized financial tables and mentions attachments of the full statements, the primary nature of this specific document is the initial announcement of the annual results and the subsequent steps for formal approval, which aligns best with an Earnings Release (ER) or, given the context of annual results and dividend proposal, it is a strong candidate for an Annual Report (10-K) disclosure, but since it is a press release summarizing the results and mentioning the formal filing is pending approval by the shareholders, it functions as the initial release of the annual performance data. However, the document is quite extensive (38,508 chars) and includes detailed financial tables and management commentary, which goes beyond a typical brief 'Earnings Release' (ER) which usually contains only key highlights. It discusses the approved draft of the full annual/consolidated statements and includes several attached financial schedules (Stato Patrimoniale, Conto Economico, etc.). This level of detail, focusing on the full year's performance and the approval of the statutory annual accounts, strongly suggests it is the primary disclosure of the annual results, which is typically covered by the 10-K filing in the US context, or the equivalent comprehensive annual report. Given the options, and the depth of the financial data presented (not just highlights, but detailed comparative tables and balance sheet excerpts), it is more than just an ER. Since it is the announcement of the *approved* annual financial statements, it is classified as the comprehensive Annual Report disclosure, even if the formal 10-K filing might follow. Revisiting the definitions: 10-K is the 'Official yearly report covering company activity and full financial performance.' This document serves as the comprehensive announcement of that performance, including the proposal for the dividend and the call for the meeting to approve the final accounts. It is the substance of the annual report being released to the market. If this were a very short document merely stating 'The annual report is available,' it would be RPA. Since it contains the core financial data and commentary, it is the report itself being disseminated via press release format. FY 2022
2023-03-31 Italian
AGGIORNAMENTO SULL’ESECUZIONE DEL PROGRAMMA DI ACQUISTO AZIONI PROPRIE
Transaction in Own Shares Classification · 98% confidence The document is an official communication from Shedir Pharma Group S.p.A. titled 'AGGIORNAMENTO SULL'ESECUZIONE DEL PROGRAMMA DI ACQUISTO AZIONI PROPRIE' (Update on the Execution of the Own Share Purchase Program). This explicitly details transactions where the company bought back its own shares during a specific period (March 20-24, 2023), including the number of shares, average price, and total consideration. This activity directly corresponds to the definition of 'Transaction in Own Shares' (share repurchase/issuance). The document is a formal announcement detailing the execution of a buyback program, not just a general regulatory filing or a report publication announcement.
2023-03-27 Italian
AGGIORNAMENTO SULL’ESECUZIONE DEL PROGRAMMA DI ACQUISTO AZIONI PROPRIE
Transaction in Own Shares Classification · 100% confidence The document is an official communication from Shedir Pharma Group S.p.A. titled 'AGGIORNAMENTO SULL'ESECUZIONE DEL PROGRAMMA DI ACQUISTO AZIONI PROPRIE' (Update on the Execution of the Own Share Purchase Program). It details the number of shares bought back, the price, and the total consideration during a specific period (March 13 to March 17, 2023). This activity—the company buying back its own shares—directly corresponds to the definition of 'Transaction in Own Shares' (POS). It is not a general earnings release (ER), a full annual report (10-K), or a management discussion (MDA), but a specific report on share repurchase activity.
2023-03-20 Italian
COMUNICAZIONE: Acquisto azioni proprie settimana 06/06/2023
Transaction in Own Shares Classification · 100% confidence The document is an official communication ('Informazione Regolamentata') from SHEDIR PHARMA GROUP dated March 13, 2023. The subject ('Oggetto') explicitly states: 'COMUNICAZIONE: Acquisto azioni proprie' (Communication: Purchase of own shares). The body of the text details the execution of a share buyback program, providing aggregated and detailed daily transaction data for the period between March 6 and March 10, 2023. This directly corresponds to the definition of 'Transaction in Own Shares' (POS), which covers company buybacks.
2023-03-13 Italian
COMUNICATO STAMPA - Shedir Pharma Group - Acquisto azioni proprie del 06.03.2023
Transaction in Own Shares Classification · 99% confidence The document is an official communication from Shedir Pharma Group S.p.A. titled 'AGGIORNAMENTO SULL'ESECUZIONE DEL PROGRAMMA DI ACQUISTO AZIONI PROPRIE' (Update on the execution of the share buyback program). It details the number of shares purchased, the price, and the total consideration paid during a specific period (Feb 27 to Mar 03, 2023). This activity—the company buying back its own shares—directly corresponds to the definition of 'Transaction in Own Shares'. The filing code for this is POS.
2023-03-06 Italian

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.